Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$20.87M$20.87Mderived+18.2% vs Q4 2024 Net Income-$9.04M-$9.04MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$13,755,000+22.6% Operating Incomederived-$6,648,000N/M Operating Cash Flowderived-$4,870,000N/M Free Cash Flowderived-$4,961,000N/M Margins · derivedGross margin65.9%+2.3 pt vs Q4 2024
Operating margin-31.9%+15.5 pt vs Q4 2024
Net margin-43.3%+8.9 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 25, 2026 · 84 d after period end